NLBNPIT201B7 20240621 480 (P201B7) News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development

TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).

CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights

Reported Full Year 2023 total revenues of 2% growth at €48.5 millionSecured approximately USD 20 million –...

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease

CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 10, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]